External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

APCN 2025

-
Coming soon
04:00 AM
Duration 2hrs Taipei, Taiwan
Suppression of complement alternative pathway with monthly dosing of sefaxersen, a novel antisense oligonucleotide therapy in development for IgAN
Jonathan Barratt

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:00 AM
Duration 2hrs Taipei, Taiwan
Evaluation of Pathophysiology Biomarkers in Kidney Biopsies Collected in IMAgINATION, a Phase 3 Study of Sefaxersen in Patients With IgA Nephropathy
Jonathan Barratt

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar